p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease (AD), neurodegenerative signals such as amyloid-beta (Aβ) and the precursors of neurotrophins, outbalance neurotrophic signals, causing synaptic dysfunction and neurodegeneration. The neurotrophin receptor p75 (p75NTR) is a receptor of Aβ and mediates Aβ-induced neurodegenerative signals. The shedding of its ectodomain from the cell surface is physiologically regulated; however, the function of the diffusible p75NTR ectodomain (p75ECD) after shedding remains largely not known. Here, we show that p75ECD levels in cerebrospinal fluid and in the brains of Alzheimer's patients and amyloid-beta precursor protein (APP)/PS1 transgenic mice were significantly reduced, due to inhibition of the sheddase-tumor necrosis factor-alpha-converting enzyme by Aβ. Restoration of p75ECD to the normal level by brain delivery of the gene encoding human p75ECD before or after Aβ deposition in the brain of APP/PS1 mice reversed the behavioral deficits and AD-type pathologies, such as Aβ deposit, apoptotic events, neuroinflammation, Tau phosphorylation and loss of dendritic spine, neuronal structures and synaptic proteins. Furthermore, p75ECD can also reduce amyloidogenesis by suppressing β-secretase expression and activities. Our data demonstrate that p75ECD is a physiologically neuroprotective molecule against Aβ toxicity and would be a novel therapeutic target and biomarker for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Sortilin is essential for proNGF-induced neuronal cell death
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004) · Nature · doi:10.1038/nature02319 · Cited by 962
p75 and Trk: A two-receptor system
Chao, M. V., & Hempstead, B. L. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93922-k · Cited by 857
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
Gene Transfer and Molecular Cloning of the Human NGF Receptor
Chao, M. V., Bothwell, M. A., Ross, A. H., Koprowski, H., Lanahan, A. A., Buck, C. R., & Sehgal, A. (1986) · Science · doi:10.1126/science.3008331 · Cited by 449 · cited 1×
“15,16,17,18 p75NTR signaling has critical roles in the plasticity of nerve innervation during development 19 and neurodegeneration after a nerve injury.”
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445
Ibáñez, C. F., & Simi, A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.03.007 · Cited by 238 · cited 1×
“…antibodies in vitro and in vivo can block the Tau phosphorylation, suggesting that A β -induced Tau phosphorylation is likely mediated by p75NTR. p75NTR also mediates apoptosis and degeneration induced by proneurotrophins, 20 and p75ECD can block neurite collapse mediated by proNGF and proBDNF.”
Developmental axon pruning mediated by BDNF-p75NTR–dependent axon degeneration
Singh, K. K., Park, K. J., Hong, E. J., Kramer, B. M., Greenberg, M. E., Kaplan, D. R., & Miller, F. D. (2008) · Nature Neuroscience · doi:10.1038/nn.2114 · Cited by 237
Cited by
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Self-citationXiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277
Self-citationPhysiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02559-z · Cited by 110
“Mice were subjected to behavioral tests, including the Y-maze test, open-field test, and Morris water maze test, as previously described [44].”
Self-citationNeurotrophin receptor p75 mediates amyloid β-induced tau pathology
Shen, L.-L., Li, W.-W., Xu, Y.-L., Gao, S.-H., Xu, M.-Y., Bu, X.-L., Liu, Y.-H., Wang, J., Zhu, J., Zeng, F., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104567 · Cited by 59
Self-citationNeurotrophin receptors in the pathogenesis, diagnosis and therapy of neurodegenerative diseases
Meldolesi, J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.024 · Cited by 53
Eggert, S., Kins, S., Endres, K., & Brigadski, T. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0330 · Cited by 46
“…receptor has been shown to interact with APP, sAPP α , sAPP β , and A β , respectively, thereby inducing either neuroprotective or neurotoxic function (Figure 3, Table 1) (Costantini et al. 2005; Fombonne et al. 2009; Hasebe et al. 2013; Saadipour et al. 2018; Yao et al. 2015; Yi et al. 2021).”
BackgroundInfluentialFinding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
Wang, Q., Wang, Y., Zhang, T., Jiao, S., Liu, Y., Zeng, F., Li, J., Yao, X., Zhou, H., Zhou, X., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13616 · Cited by 41
Self-citationDing, X.-W., Li, R., Geetha, T., Tao, Y.-X., & Babu, J. R. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165858 · Cited by 36
ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology
Cao, Y., Xu, H., Zhu, Y., Shi, M.-J., Wei, L., Zhang, J., Cheng, S., Shi, Y., Tong, H., Kang, L., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000313 · Cited by 31
“Virus-mediated expression of ADAMTS13 reverses BBB breakdown and microvascular and cerebral blood flow reductions in APPPS1 mice Next, we studied the role of ADAMTS13 in APPPS1 mice by injecting recombinant adenoassociated virus serotype 8 (AAV8)-mediated expression of a murine ADAMTS13 variant (AAV8-ADAMTS13) into th…”
BackgroundSelf-citationRetracted
Metadata
- Authors
- Yao, X.-Q., Jiao, S.-S., Saadipour, K., Zeng, F., Wang, Q.-H., Zhu, C., Shen, L.-L., Zeng, G.-H., Liang, C.-R., Wang, J., Liu, Y.-H., Hou, H.-Y., Xu, X., Su, Y.-P., Fan, X.-T., Xiao, H.-L., Lue, L.-F., Zeng, Y.-Q., Giunta, B., Zhong, J.-H., Walker, D. G., Zhou, H.-D., Tan, J., Zhou, X.-F., & Wang, Y.-J.
- Venue
- Molecular Psychiatry
- Published
- 2015-04-28
- Volume
- 20
- Issue
- 11
- Pages
- 1301-1310
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2022980912
- Cited by
- 110
- References
- 8
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.